Cell:GWAS分析发现亨廷顿氏病潜在治疗靶基因

2015-08-05 佚名 生物谷

来自美国马萨诸塞总医院的研究人员利用GWAS分析方法对影响亨廷顿氏病发生的遗传因素进行了研究,最终发现了两个以上可以加快或延迟该疾病发生的基因突变。相关研究结果发表在国际学术期刊Cell上。

                                                                

最近,来自美国马萨诸塞总医院的研究人员利用GWAS分析方法对影响亨廷顿氏病发生的遗传因素进行了研究,最终发现了两个以上可以加快或延迟该疾病发生的基因突变。相关研究结果发表在国际学术期刊Cell上。

在这项由多个研究所合作完成的研究中,研究人员对超过4000名HD病人的样本进行全基因组关联分析(GWAS),发现在两个染色体出现的特定基因突变在首次出现HD相关运动障碍的个体中非常常见。

研究人员指出,之前许多研究都将研究重点放在细胞或动物模型中出现的突变蛋白,但这些生物过程发生的异常与病人体内发生的变化之间究竟存在什么样的关联仍然存在巨大疑问。

在这项研究中,研究人员从HD病人身上收集了大量DNA样本,随后对这些DNA样本进行扫描分析,寻找每个病人开始出现运动障碍与按照预测应该出现运动障碍之间存在差异性的DNA突变,最终在15号染色体的两个位置发现了与HD早发或迟发显著相关的基因突变。

随后,研究人员又与美国和欧洲的研究小组进行合作,对2131名病人进行了GWAS分析,并将所有数据整合在一起,加强了15号染色体两个基因突变与HD发病之间的关联性,除此之外,研究人员还在8号染色体上发现了第三个与HD发病存在显著关联的基因突变,研究结果还表明在3号,5号和21号染色体上也存在一些可能与HD发病有关的基因突变,但关联性不强。

研究人员指出,这项研究不依赖于体外模型,而是利用病人DNA样品和临床数据进行分析,发现了除HD基因之外参与HD疾病发生的其他基因突变,而接下来的工作就应该着重研究这些基因突变如何影响HD发生,并开发相关的治疗方法。

原始出处:

 
Conceptualization, J.-M.L., M.E.M., J.F.G., L.J., and S.K.; resources, R.H.M.et al.Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.18 June.2015
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959427, encodeId=3f0c195942efe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 29 07:55:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869172, encodeId=c10318691e27f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 03 06:55:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280033, encodeId=9cfe1280033c3, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313176, encodeId=526013131e644, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622737, encodeId=0ec11622e37bd, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35145, encodeId=216e351458f, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:20:00 CST 2015, time=2015-08-06, status=1, ipAttribution=)]
    2016-04-29 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959427, encodeId=3f0c195942efe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 29 07:55:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869172, encodeId=c10318691e27f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 03 06:55:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280033, encodeId=9cfe1280033c3, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313176, encodeId=526013131e644, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622737, encodeId=0ec11622e37bd, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35145, encodeId=216e351458f, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:20:00 CST 2015, time=2015-08-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959427, encodeId=3f0c195942efe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 29 07:55:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869172, encodeId=c10318691e27f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 03 06:55:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280033, encodeId=9cfe1280033c3, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313176, encodeId=526013131e644, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622737, encodeId=0ec11622e37bd, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35145, encodeId=216e351458f, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:20:00 CST 2015, time=2015-08-06, status=1, ipAttribution=)]
    2015-08-06 lxg951
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959427, encodeId=3f0c195942efe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 29 07:55:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869172, encodeId=c10318691e27f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 03 06:55:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280033, encodeId=9cfe1280033c3, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313176, encodeId=526013131e644, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622737, encodeId=0ec11622e37bd, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35145, encodeId=216e351458f, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:20:00 CST 2015, time=2015-08-06, status=1, ipAttribution=)]
    2015-08-06 chengjn
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959427, encodeId=3f0c195942efe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 29 07:55:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869172, encodeId=c10318691e27f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 03 06:55:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280033, encodeId=9cfe1280033c3, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313176, encodeId=526013131e644, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622737, encodeId=0ec11622e37bd, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35145, encodeId=216e351458f, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:20:00 CST 2015, time=2015-08-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1959427, encodeId=3f0c195942efe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 29 07:55:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869172, encodeId=c10318691e27f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 03 06:55:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280033, encodeId=9cfe1280033c3, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313176, encodeId=526013131e644, content=<a href='/topic/show?id=64dd9996046' target=_blank style='color:#2F92EE;'>#靶基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99960, encryptionId=64dd9996046, topicName=靶基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622737, encodeId=0ec11622e37bd, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Aug 06 23:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35145, encodeId=216e351458f, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:20:00 CST 2015, time=2015-08-06, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

相关资讯

维莫斯遭遇连环打击,肾癌患者获数月生命

【新闻事件】:今天诺华制药的mTOR抑制剂依维莫斯在肾癌市场遭遇来自施贵宝和Exelixis的组合重拳打击。首先是Exelixis宣布其cMet抑制剂Cometriq(通用名cabozantinib)在一个叫做METEOR的晚期肾癌三期临床实验中达到一级终点,作为二线药物比依维莫斯显着延长无进展生存期。总生存期估计明年年初会有结果,但据中期分析显示有延长趋势。不到一小时,施贵宝宣布其PD-1抑

里程碑:GSK向欧盟申请基因治疗上市

2015年5月5日,葛兰素史克公司(GlaxoSmithKline,GSK)正式向欧盟药监局(EMA)提交了ADA-SCID(腺苷脱氨酶缺陷所致重症联合免疫缺陷症)基因治疗方法(代号:GSK2696273)的上市申请。这一基因治疗方法首先提取患者自身离体(ex vivo)造血干细胞,并在体外培养。然后利用逆转录病毒将正常ADA(腺苷脱氨酶)基因导入自体造血干细胞。最后将改造后的干细胞回输患者体

NEJM:基因治疗不能一劳永逸,几年内疗效会下降

被寄予厚望的基因疗法可能无法像人们预想的那样彻底解决问题。顶级医学期刊发布的两项临床试验表明,旨在恢复视力的基因疗法会在几年内失效。 这并不算是特别惊人的消息,俄勒冈健康与科学大学的眼病研究者Mark Pennesi说,“这些疾病比较复杂,而这只是第一代基因疗法。”Pennesi正在进行类似的临床试验。 Leber先天黑蒙LCA是一种罕见的遗传性失明,患者在四十岁左右会完全丧失视力。大

Lancet:CFTR基因治疗对肺囊性纤维化有一定效果

    背景  与阳离子脂质体复合的编码CFTR基因的质粒DNA是肺囊性纤维化患者的潜在的治疗选择。该研究的目的是评估在囊性纤维化患者的非病毒CFTR基因疗法的疗效。    方法  研究人员在英国18个地点的2个囊性纤维化患者中心的患者做这项随机,双盲,安慰剂对照,2b期试验。患者(年龄≥12岁)在1秒内用力呼气呼气量(FEV1)预测为5

STM:基因治疗使小鼠恢复听力,遗传性耳聋有望治愈

波士顿儿童医院和哈佛医学院的研究人员通过基因治疗为“耳聋”小鼠模型恢复了听力,其研究成果于7月8日在线发表在Science Translational Medicine杂志上,这将推动基因治疗应用于遗传性耳聋治疗的进程。波士顿儿童医院的科学家Jeffrey Holt说:“我们的基因治疗方法尚未用于临床实验,还需再优化,并在不久的将来将其用于治疗耳聋患者。”目前已发现超过70个基因与耳聋相关(实

诺华抗癌药Odomzo获FDA加速批准用于局部晚期基底细胞癌

瑞士制药巨头诺华(Novartis)抗癌管线近日在监管方面收获喜讯,FDA加速批准Odomzo(sonidegib,200mg)用于经手术或放射治疗后病情复发、以及不适合这2种治疗方案的局部晚期基底细胞癌(laBCC)成人患者。此前,Odomzo已于今年6月30日获瑞士批准,并于6月25日获得欧盟CHMP建议批准的积极意见。 基底细胞癌(BCC)是一种最常见的皮肤癌,约占非黑色素瘤皮肤癌的80%